TXG 10x Genomics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TXG

Price (delayed)

$64.85

Market cap

$8.45B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.59

Enterprise value

$8.03B

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 99
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 37
Highlights
TXG's EPS is up by 17% year-on-year
The company's net income rose by 11% YoY
10x Genomics's revenue has decreased by 4.3% YoY and by 3.4% from the previous quarter
The company's gross profit fell by 3.5% YoY and by 2.8% QoQ
Sector: Healthcare
Industry: Health Information Services
Website: http://www.10xgenomics.com
Peers: NVAX NVCR NBIX

Key stats

What are the main financial stats of TXG

TXG stock price

How has the 10x Genomics stock price performed over time
Intraday
0.92%
1 week
1.53%
1 month
41.22%
1 year
362.55%
YTD
297.61%
QTD
69.14%

Financial performance

How have 10x Genomics's revenue and profit performed over time
Revenue
$616.91M
Gross profit
$432.03M
Operating income
-$88.38M
Net income
-$75.13M
Gross margin
70%
Net margin
-12.2%
10x Genomics's operating margin has shrunk by 134% QoQ but it has increased by 8% YoY
TXG's operating income has dropped by 128% since the previous quarter but it is up by 12% year-on-year
The company's net income rose by 11% YoY
10x Genomics's net margin has increased by 7% YoY

Price vs fundamentals

How does TXG's price correlate with its fundamentals

Growth

What is 10x Genomics's growth rate over time

Valuation

What is 10x Genomics stock price valuation
P/E
N/A
P/B
9.97
P/S
13.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.01
TXG's EPS is up by 17% year-on-year
The P/B is 193% above the last 4 quarters average of 3.4 and 51% above the 5-year quarterly average of 6.6
TXG's equity is up by 7% year-on-year
The stock's price to sales (P/S) is 42% more than its 5-year quarterly average of 9.6
10x Genomics's revenue has decreased by 4.3% YoY and by 3.4% from the previous quarter

Efficiency

How efficient is 10x Genomics business performance
The ROE has grown by 20% YoY
TXG's ROA is up by 19% YoY
The return on invested capital has declined by 10% year-on-year

Dividends

What is TXG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TXG.

Financial health

How did 10x Genomics financials performed over time
TXG's total assets is up by 5% year-on-year
The current ratio has contracted by 3.6% from the previous quarter and by 2.6% YoY
10x Genomics's debt is 90% lower than its equity
10x Genomics's debt has decreased by 9% YoY and by 3.2% QoQ
10x Genomics's debt to equity has decreased by 9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.